New York, NY (PRWEB) January 14, 2014
As dozens of Lipitor lawsuits (http://www.thelipitorlawsuit.com/ ) alleging use of the statin caused patients to develop Type 2 diabetes continue to move forward in courts around the country, Bernstein Liebhard LLP notes that Pfizer Inc. has also been named a defendant in a new whistleblower lawsuit involving the cholesterol-lowering medication. The complaint, which was filed on behalf of the federal government by Health Support Awareness Inc., accuses Pfizer of deceptively marketing Lipitor in a way that resulted in fraud against Medicare, Medicaid and others. The Lipitor whistleblower lawsuit, which was unsealed on January 10, 2014 in the U.S. District Court, District of Massachusetts, was filed under the federal False Claims Act, a law which allows private citizens or entities to bring suit against defendants that have allegedly defrauded the U.S. government. (United States of American vs. Pfizer Inc., 1:13-cv-11917)
“Numerous Lipitor lawsuits have already been filed against Pfizer by individuals who were allegedly harmed by this drug. We will be monitoring the progress of this whistleblower lawsuit very closely, as such cases often bring evidence to light that might be relevant in other claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to anyone who may have developed new-onset Type 2 diabetes due to the use of this statin medication.
According to court documents, Pfizer has been named in at least 100 product liability lawsuits that allege a connection between Lipitor and diabetes. On January 30, 2014, the U.S. Judicial Panel on Multidistrict Litigation will hear oral arguments regarding the possible consolidation of federally-filed Lipitor diabetes claims in a single jurisdiction for pretrial proceedings. All of these lawsuits accuse Pfizer of failing to provide adequate warnings regarding the risks associated with the statin medication. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))
In February 2012, the U.S. Food & Drug Administration (FDA) ordered Pfizer to add new warnings to the Lipitor label regarding its possible association with an increased risk of new-onset Type 2 diabetes. The FDA acted after research published in JAMA: Internal Medicine reported that post-menopausal women treated with statins were at increased risk of developing diabetes.*
In May 2013, the British Medical Journal published a study which found Lipitor patients faced a 22 percent increased risk of developing Type 2 diabetes.**
Individuals who allegedly developed diabetes due to their use of Lipitor may be entitled to compensation from Pfizer. To find out more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
**bmj.com/content/346/bmj.f2610, BMJ, May 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11488510.htm.
Copyright©2012 Vocus, Inc.
All rights reserved